{"filing":{"accession_number":"0001213900-26-083664","cik":"0001783036","ticker":"NCEL","company_name":"NewcelX Ltd.","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0300034-6k_newcelx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783036/000121390026083664/ea0300034-6k_newcelx.htm"},"events":[{"id":22330,"run_id":20192,"accession_number":"0001213900-26-083664","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"NewcelX announced a private placement of 347,134 common shares and warrants at $4.033 per share (20% premium to market), raising $1.4 million in unregistered equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, material to investors assessing ownership dilution and the company's capital structure.","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22249,"accession_number":"0001213900-26-083664","item_number":"EX-99.1","item_title":"ea030003402ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NewcelX announced a private placement of 347,134 common shares and warrants at $4.033 per share (20% premium to market), raising $1.4 million in unregistered equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:03:05.080607+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22249,"accession_number":"0001213900-26-083664","item_number":"EX-99.1","item_title":"ea030003402ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NewcelX announced a private placement of 347,134 common shares and warrants at $4.033 per share (20% premium to market), raising $1.4 million in unregistered equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, material to investors assessing ownership dilution and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:03:05.080607+00:00","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-31"}]}